OBJECTIVE: To quantify preference for disclosure of information among patients with rheumatoid arthritis (RA) and to examine sex-specific correlates of information preference. METHODS: We interviewed patients with RA and assessed preference for disclosure of information using 4 questions from the previously validated "Information Preference Seeking Scale." Three questions addressed preference for disclosure of side effects and 1 question addressed preference for disclosure of therapeutic options. Associations between preference for information and patient characteristics were examined using stepwise multiple linear regression. RESULTS: One hundred RA patients (mean age 68+/-12 years; 73% female) were interviewed; 89 respondents agreed or strongly agreed with all 4 statements reflecting a preference for full disclosure, and an additional 8 respondents agreed or strongly agreed with 3 of the 4 statements. The mean score (+/- SD) for information preference was 86+/-13, on a scale from 0 to 100 where 100 reflected a strong preference for full disclosure. In bivariate analyses, female sex and current employment were associated with stronger preferences for being informed (mean score for women 88+/-11, for men 80+/-15 [P = 0.02]; for employed 92+/-11, for unemployed 84+/-13 [P = 0.04]). Multivariate sex-specific analyses demonstrated that current employment and higher education level were positively associated with preference for disclosure among women and men, respectively. CONCLUSION: The results of our survey suggest that RA patients want to be fully informed about the risks associated with medications and about alternative options. The challenge remaining for rheumatologists is how to effectively communicate the risks and benefits related to the many options that are currently available for RA patients.
OBJECTIVE: To quantify preference for disclosure of information among patients with rheumatoid arthritis (RA) and to examine sex-specific correlates of information preference. METHODS: We interviewed patients with RA and assessed preference for disclosure of information using 4 questions from the previously validated "Information Preference Seeking Scale." Three questions addressed preference for disclosure of side effects and 1 question addressed preference for disclosure of therapeutic options. Associations between preference for information and patient characteristics were examined using stepwise multiple linear regression. RESULTS: One hundred RApatients (mean age 68+/-12 years; 73% female) were interviewed; 89 respondents agreed or strongly agreed with all 4 statements reflecting a preference for full disclosure, and an additional 8 respondents agreed or strongly agreed with 3 of the 4 statements. The mean score (+/- SD) for information preference was 86+/-13, on a scale from 0 to 100 where 100 reflected a strong preference for full disclosure. In bivariate analyses, female sex and current employment were associated with stronger preferences for being informed (mean score for women 88+/-11, for men 80+/-15 [P = 0.02]; for employed 92+/-11, for unemployed 84+/-13 [P = 0.04]). Multivariate sex-specific analyses demonstrated that current employment and higher education level were positively associated with preference for disclosure among women and men, respectively. CONCLUSION: The results of our survey suggest that RApatients want to be fully informed about the risks associated with medications and about alternative options. The challenge remaining for rheumatologists is how to effectively communicate the risks and benefits related to the many options that are currently available for RApatients.
Authors: Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna Journal: Arthritis Care Res (Hoboken) Date: 2012-07 Impact factor: 4.794
Authors: E D Hale; G J Treharne; A C Lyons; Y Norton; S Mole; D L Mitton; K M J Douglas; N Erb; G D Kitas Journal: Ann Rheum Dis Date: 2005-10-11 Impact factor: 19.103
Authors: Suz Jack Chan; Lisa K Stamp; Nicola Liebergreen; Henry Ndukwe; Carlo Marra; Gareth J Treharne Journal: Patient Date: 2020-04 Impact factor: 3.883
Authors: Ingrid Nota; Constance H C Drossaert; Erik Taal; Harald E Vonkeman; Cees J Haagsma; Mart A F J van de Laar Journal: Arthritis Res Ther Date: 2016-10-28 Impact factor: 5.156
Authors: Ingrid Nota; Constance H C Drossaert; Heleen C Melissant; Erik Taal; Harald E Vonkeman; Cees J Haagsma; Mart A F J van de Laar Journal: BMC Med Inform Decis Mak Date: 2017-04-26 Impact factor: 2.796
Authors: Ilana N Ackerman; Joanne E Jordan; Sharon Van Doornum; Margaret Ricardo; Andrew M Briggs Journal: BMC Musculoskelet Disord Date: 2015-08-19 Impact factor: 2.362
Authors: Neena S Abraham; Aanand D Naik; Richard L Street; Diana L Castillo; Anita Deswal; Peter A Richardson; Christine M Hartman; George Shelton; Liana Fraenkel Journal: Patient Prefer Adherence Date: 2015-11-19 Impact factor: 2.711